FDA advisers are scrutinizing Eli Lilly's application for an Alzheimer's drug, potentially shaping the future approach to amyloid plaque-targeting treatments.
Issues such as changes in cognitive function measures, tau protein assessment, and safety concerns are sparking debates between the FDA and Lilly.
Collection
[
|
...
]